The MTD on the daily dosing schedule for patients with solid tumors (500 mg for QD × 5 or 1000 mg for QD × 3) is significantly lower than the 600-mg BID dose in the MBP formulation used in patients with relapsed/refractory acute myeloid leukemia in whom hematologic effects are a desired outcome [17]. Here, MBP is linked to acute myeloid leukemia.